AI睡眠診斷
Honeynaps 旗下AI診斷軟件獲美國FDA批准
HoneyNaps 旗下的 SOMNUM V3.0 獲美國 FDA 510(k) 許可，這是一套以人工智能驅動的診斷軟件平台，設計用於協助臨床醫生進行多導睡眠圖分析。系統可自動偵測呼吸暫停及低通氣事件，並運用人工智能演算法將呼吸暫停分類為阻塞性、中樞性或混合性。
提交予 FDA 的驗證數據顯示，各呼吸事件類別的整體一致率超過 97%。HoneyNaps 早前已為 SOMNUM V1.1.2 取得 510(k) 許可，並計劃為未來版本爭取更多批准，屆時將可偵測包括缺氧負荷、覺醒負荷及通氣負荷等數碼生物標記。
對臨床醫生而言，SOMNUM V3.0 可減少審閱睡眠檢測數據所需的人手工作量，同時將呼吸事件分析標準化。此次許可反映業界持續採用人工智能輔助診斷工具，以簡化專科工作流程，並支持更一致的臨床判讀。
英文原文
HoneyNaps received U.S. FDA 510(k) clearance for SOMNUM V3.0, an AI-powered diagnostic software platform designed to assist clinicians with polysomnography analysis. The system automatically detects apnea and hypopnea events and classifies apnea as obstructive, central or mixed using AI algorithms.
Validation data submitted to the FDA showed more than 97% Overall Percent Agreement across respiratory event categories. HoneyNaps previously received 510(k) clearance for SOMNUM V1.1.2 and plans to pursue additional approvals for future versions capable of detecting digital biomarkers including hypoxic burden, arousal burden and ventilatory burden.
For clinicians, SOMNUM V3.0 can reduce the manual workload involved in reviewing sleep-study data while standardizing respiratory event analysis. The clearance reflects continued adoption of AI-assisted diagnostic tools designed to streamline specialist workflows and support more consistent clinical interpretation.
- 來源
- Trend Hunter
- 發布
- 2026-08-14
- 品類
- Ai
- 出處
- mobihealthnews